Your session is about to expire
← Back to Search
Hormone Therapy
Kisspeptin in the Evaluation of Delayed Puberty
Phase 1
Waitlist Available
Led By Stephanie B Seminara, MD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial tests if certain hormones can predict whether delayed puberty in children will resolve on its own or need treatment. It involves children with delayed puberty. The hormones signal the body to start puberty, helping doctors determine if the delay is temporary or permanent.
Eligible Conditions
- Delayed Puberty
- Hypogonadotropic hypogonadism
- Kallmann Syndrome
- Gonadotropin-Releasing Hormone Deficiency
- Hypogonadotropic Hypogonadism
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Side effects data
From 2009 Phase 2 trial • 36 Patients • NCT0058689822%
Hyperglycemia
19%
Hot Flashes
17%
Dyspnea
14%
Hyperkalemia
8%
SGPT (ALT)
6%
Hypoglycemia
3%
Pneumonitis
3%
Cardiovascular, other
100%
80%
60%
40%
20%
0%
Study treatment Arm
All Participants
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Kisspeptin, GnRHExperimental Treatment2 Interventions
Intravenous (IV) administration of kisspeptin 112-121 0.24 nmol/kg and GnRH 75 ng/kg
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
GnRH
2017
Completed Phase 2
~640
kisspeptin 112-121
2013
Completed Phase 1
~420
Find a Location
Who is running the clinical trial?
Massachusetts General HospitalLead Sponsor
3,026 Previous Clinical Trials
13,413,775 Total Patients Enrolled
Stephanie B Seminara, MDPrincipal InvestigatorMassachusetts General Hospital
8 Previous Clinical Trials
5,149 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- This study is not open to teenage boys.You have not experienced any breast development changes in the past 6 months and are in the early stages of puberty.The study does not allow participation of teenage girls.You are between 13.5 and 17 years old.Your bones are not as developed as they should be for your age.You are between the ages of 12 and 17.
Research Study Groups:
This trial has the following groups:- Group 1: Kisspeptin, GnRH
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.